Huntington Beach, California – July 28, 2026 — Leonhardt Ventures LLC, in collaboration with Lionheart Health, Inc. and CancerCell, Inc., today announced the preparation of a new U.S. provisional patent application covering novel methods and systems for the bioelectric stimulation and expression of thymulin for a broad range of potential therapeutic applications.
The patent application expands the Leonhardt portfolio of bioelectric medicine inventions by targeting thymulin, a naturally occurring thymic peptide that plays an important role in immune regulation, T-cell maturation, inflammation control, and healthy aging.
The invention includes proprietary bioelectric stimulation protocols, device configurations, treatment systems, wearable technologies, implantable systems, injectable biomaterial platforms, and combination therapies designed to safely increase endogenous thymulin expression or enhance thymulin-based regenerative therapies.
Potential applications described in the provisional patent include:
- Immune system rejuvenation
- Healthy aging and longevity programs
- Cancer immunotherapy support
- Autoimmune disease modulation
- Chronic inflammatory disorders
- Infectious disease recovery
- Stem cell enhancement
- Tissue regeneration and wound healing
- Frailty and age-related immune decline
- Surgical recovery
- Vaccine response enhancement
- Organ regeneration protocols
- Combination therapies with Klotho, stem cells, exosomes, peptides, red light therapy, PEMF, exercise, nutrition, and additional bioelectric medicine technologies
The patent filing is intended to complement Leonhardt Ventures’ growing intellectual property portfolio focused on using precisely targeted bioelectric stimulation to safely activate regenerative proteins and signaling pathways within the body.
“Our vision is to develop non-drug approaches that encourage the body to produce its own regenerative molecules,” said Howard J. Leonhardt, Founder and Managing Partner of Leonhardt Ventures LLC and Executive Chairman & Co-CEO of Lionheart Health. “Thymulin represents another exciting biologic target that may help restore immune resilience and improve regenerative capacity as people age. We believe bioelectric medicine offers a unique opportunity to influence these pathways in a precise, personalized, and non-invasive manner.”
CancerCell is expected to investigate potential oncology applications of thymulin bioelectric expression, while Lionheart Health plans to evaluate its role within the company’s expanding multi-modality longevity and health optimization programs.
The new invention builds upon Leonhardt Ventures’ extensive bioelectric medicine intellectual property portfolio, which now encompasses more than 800 patent claims covering regenerative medicine, longevity, neuromodulation, cardiovascular therapies, orthopedic applications, stem cell enhancement, tissue regeneration, and expression of multiple therapeutic proteins.
Preclinical laboratory studies and future clinical investigations are expected to evaluate the safety and potential biological effects of bioelectric thymulin expression across a variety of indications. Any therapeutic applications remain investigational and have not been approved by the U.S. Food and Drug Administration.
About Leonhardt Ventures LLC
Founded in 1982, Leonhardt Ventures LLC is a medical technology innovation company focused on regenerative medicine, bioelectric therapeutics, longevity technologies, cardiovascular therapies, and advanced biologic treatment platforms. Its portfolio companies have developed numerous FDA-cleared medical technologies and continue to advance next-generation regenerative therapies.
About Lionheart Health, Inc.
Lionheart Health is developing integrated longevity and health optimization programs combining bioelectric medicine, regenerative biologics, diagnostics, nutrition, exercise, artificial intelligence, and personalized wellness protocols designed to improve healthy lifespan.
About CancerCell, Inc.
CancerCell, Inc. is developing innovative technologies designed to improve cancer treatment through regenerative medicine, bioelectric therapeutics, precision medicine, and advanced immune system modulation.
Media Contact
Howard J. Leonhardt
Executive Chairman & Co-CEO
Lionheart Health, Inc.
Founder & Managing Partner
Scientific Background on Thymulin
- Bach JF, Dardenne M.
Thymulin, a zinc-dependent hormone.
Medical Oncology and Tumor Pharmacotherapy. 1989;6(1):25-29.- Classic review describing thymulin biology, zinc dependence, T-cell differentiation, and immune regulation.
- Dardenne M, Bach JF.
Thymulin: Biochemistry, Biology and Therapeutical Applications.
Memórias do Instituto Oswaldo Cruz. 1987;82(Suppl II):1-8.- One of the earliest reviews discussing therapeutic applications of thymulin.
Immunology & Immune Restoration
- Savino W, Dardenne M.
Thymulin and its role in immunomodulation.
Journal of Autoimmunity. 1992;5:547-555.- Reviews thymulin’s regulation of T-cell maturation, immune deficiency, autoimmune disease, and neuroimmune interactions.
- Bach JF, et al.
Multiple studies demonstrating thymulin promotes:- T-cell differentiation
- Helper T-cell function
- Regulatory T-cell activity
- Natural killer cell activity
- Immune homeostasis
Aging & Longevity
- Reggiani PC, et al.
Physiology and therapeutic potential of the thymic peptide thymulin.
Current Pharmaceutical Design. 2014.- Comprehensive review covering aging, neuroendocrine regulation, anti-inflammatory actions, and thymulin gene therapy.
- Kanemaru H, et al.
Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy.
Nature Communications. 2026.- Demonstrated that thymulin declines with age, suppresses NF-κB-mediated inflammation, restores immune competence in aged animals, improves antitumor immunity, and enhances response to anti-PD-L1 therapy.
Cancer Immunotherapy
- Kanemaru H, et al.
Nature Communications. 2026.
Major findings:- Reduced IL-1β
- Reduced IL-6
- Reduced TNF-α
- Improved CD8 T-cell activity
- Enhanced checkpoint inhibitor response
- Reduced tumor growth in aged mice
Anti-inflammatory Effects
- Reggiani PC, et al.
Evidence supporting thymulin as:- anti-inflammatory
- analgesic
- neuroprotective
- neuroendocrine regulator
- candidate gene therapy target
- Experimental studies reviewed in:
Savino & Dardenne (1992)
demonstrating inhibition of inflammatory cytokines and restoration of immune balance.
Neuroendocrine Regulation
- Reggiani PC, et al.
Demonstrated interactions between:
- pituitary hormones
- thymus
- hypothalamus
- reproductive hormones
- aging endocrine function
Gene Therapy
- Reggiani PC, et al.
Review of adenoviral thymulin gene therapy restoring circulating thymulin levels in animal models and improving endocrine and immune abnormalities.
Modern Review
- Besman M, Zambrowicz A, Matwiejczyk M.
Review of Thymic Peptides and Hormones: From Their Properties to Clinical Application.
International Journal of Peptide Research and Therapeutics. 2025.
Comprehensive review discussing:
- thymulin
- thymosin α1
- thymopoietin
- thymic extracts
- immune modulation
- cancer
- infection
- wound healing
- regenerative medicine
Key Clinical and Translational Concepts Supported by the Literature
Current evidence suggests thymulin may have therapeutic potential in:
- Immune senescence (age-related immune decline)
- Cancer immunotherapy adjuncts
- Chronic inflammation
- Autoimmune diseases
- Immunodeficiency
- T-cell regeneration
- Vaccine responsiveness
- Wound healing and tissue repair
- Neuroimmune disorders
- Healthy aging and longevity research
- Gene therapy approaches to restore thymic hormone function
Forward-Looking Statements